Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study:

A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Rationale:

n/a

Purpose:

The primary objective of this study is to determine the safety, tolerability, and plasma pharmacokinetics of KD019 when administered to subjects with ADPKD.

Study Status: Recruiting

Recruiting:
Susan Marczewski, RN 216-444-5228 MARCZES@ccf.org

Condition Intervention Phase
Polycystic Kidney, Autosomal Dominant Drug: KD019 Phase 1/Phase 2

Verified by Kadmon Corporation, LLC January, 2014

Sponsored by: Kadmon Corporation, LLC
Information provided by: Kadmon Corporation, LLC
ClinicalTrials.gov identifier: NCT01559363

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site